136 related articles for article (PubMed ID: 34465471)
1. Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: Case-control and time-trend studies.
Baqui AH; Koffi AK; McCollum ED; Roy AD; Chowdhury NH; Rafiqullah I; Ahmed ZB; Mahmud A; Begum N; Ahmed S; Khanam R; Harrison M; Simmons N; Hossen S; Islam M; Quaiyum A; Checkley W; Santosham M; Moulton LH; Saha SK;
Vaccine; 2021 Sep; 39(40):5794-5801. PubMed ID: 34465471
[TBL] [Abstract][Full Text] [Related]
2. Population-based incidence and serotype distribution of invasive pneumococcal disease prior to introduction of conjugate pneumococcal vaccine in Bangladesh.
Baqui AH; McCollum ED; Mahmud A; Roy A; Chowdhury NH; Rafiqullah I; Rizvi SJR; Begum N; Mitra DK; Khanam R; Harrison M; Ahmed S; Hasanuzzaman M; Rahman H; Islam M; Ahmed ZB; Quaiyum MA; Koffi A; Simmons N; Checkley W; Moulton LH; Santosham M; Saha SK;
PLoS One; 2020; 15(2):e0228799. PubMed ID: 32053640
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
Malaker R; Hasanuzzaman M; Hooda Y; Rahman H; Chandra Das R; Kanon N; Saha S; Tanmoy AM; Ranjan Chakraborty S; Saha S; Islam M; Darmstadt GL; Baqui AH; Sathosam M; El-Arifeen S; Whitney CG; Saha SK
Vaccine; 2024 Jan; 42(2):255-262. PubMed ID: 38071104
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic pneumonia among children in rural Bangladesh: A case-control study.
McCollum ED; Ahmed S; Roy AD; Chowdhury NH; Schuh HB; Rizvi SJR; Hanif AAM; Khan AM; Mahmud A; Pervaiz F; Harrison M; Reller ME; Simmons N; Quaiyum A; Begum N; Santosham M; Checkley W; Moulton LH; Baqui AH;
Vaccine; 2020 Sep; 38(42):6508-6516. PubMed ID: 32873404
[TBL] [Abstract][Full Text] [Related]
5. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
6. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
[TBL] [Abstract][Full Text] [Related]
7. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U
PLoS One; 2019; 14(1):e0210081. PubMed ID: 30629620
[TBL] [Abstract][Full Text] [Related]
8. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
Palmu AA; Kilpi TM; Rinta-Kokko H; Nohynek H; Toropainen M; Nuorti JP; Jokinen J
Pediatrics; 2015 Jul; 136(1):e22-7. PubMed ID: 26077477
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal Conjugate Vaccine impact assessment in Bangladesh.
Baqui AH; McCollum ED; Saha SK; Roy AK; Chowdhury NH; Harrison M; Hanif AAM; Simmons N; Mahmud A; Begum N; Ahmed S; Khan AM; Ahmed ZB; Islam M; Mitra D; Quaiyum A; Chavez MA; Pervaiz F; Miele CH; Schuh HB; Khanam R; Checkley W; Moulton LH; Santosham M
Gates Open Res; 2018 Apr; 2():21. PubMed ID: 29984359
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan.
Riaz A; Mohiuddin S; Husain S; Yousafzai MT; Sajid M; Kabir F; Rehman NU; Mirza W; Salam B; Nadeem N; Pardhan K; Khan KMA; Raza SJ; Arif F; Iqbal K; Zuberi HK; Whitney CG; Omer SB; Zaidi AKM; Ali A;
Int J Infect Dis; 2019 Mar; 80():28-33. PubMed ID: 30576865
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.
Andrade AL; Minamisava R; Policena G; Cristo EB; Domingues CM; de Cunto Brandileone MC; Almeida SC; Toscano CM; Bierrenbach AL
Hum Vaccin Immunother; 2016; 12(2):285-92. PubMed ID: 26905679
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic.
Tomczyk S; Lessa FC; Sánchez J; Peña C; Fernández J; Gloria Carvalho M; Pimenta F; Cedano D; Whitney CG; Verani JR; Coradin H; Garib Z; De Oliveira LH; Feris-Iglesias J
BMC Infect Dis; 2018 Apr; 18(1):152. PubMed ID: 29609548
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland.
Rinta-Kokko H; Auranen K; Toropainen M; Nuorti JP; Nohynek H; Siira L; Palmu AA
Vaccine; 2020 Feb; 38(6):1559-1564. PubMed ID: 31791813
[TBL] [Abstract][Full Text] [Related]
16. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.
Jokinen J; Rinta-Kokko H; Siira L; Palmu AA; Virtanen MJ; Nohynek H; Virolainen-Julkunen A; Toropainen M; Nuorti JP
PLoS One; 2015; 10(3):e0120290. PubMed ID: 25781031
[TBL] [Abstract][Full Text] [Related]
17. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
18. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010.
Thoon KC; Chong CY; Tee NW
Int J Infect Dis; 2012 Mar; 16(3):e209-15. PubMed ID: 22281191
[TBL] [Abstract][Full Text] [Related]
19. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
Peckeu L; van der Ende A; de Melker HE; Sanders EAM; Knol MJ
Vaccine; 2021 Jan; 39(2):431-437. PubMed ID: 33243632
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
